Notable
RC288 · Solid Tumors
Recruitment opened
Also in this update: Trial sites expanded: 1 → 14 locations
RemeGen Co., Ltd.Phase 1/2 NCT07537881 Registry history of NCT07537881 on ClinicalTrials.gov (opens the registry)
Updated
28 active trials 21 recruiting 12 Phase 3 7 disease areas 4 changes in 30 days
3 trials changed in the last 30 days: 0 stopped, 1 with a notable change, 2 with minor changes only.
Recruitment opened
Also in this update: Trial sites expanded: 1 → 14 locations
RemeGen Co., Ltd.Phase 1/2 NCT07537881 Registry history of NCT07537881 on ClinicalTrials.gov (opens the registry)
Updated
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
RemeGen Co., Ltd.Phase 1/2 NCT06038396 Registry history of NCT06038396 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
RemeGen Co., Ltd.Phase 2 NCT05680480 Registry history of NCT05680480 on ClinicalTrials.gov (opens the registry)
Changed
Registry verification sweep
Changed
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-09-21 | NCT07829549 Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as… | Phase 3 | Not Yet Recruiting |
| Phase 1 | 2 | |
| Phase 1/2 | 6 | |
| Phase 2 | 8 | |
| Phase 2/3 | 3 | |
| Phase 3 | 9 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT04400695 | A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer… | Breast Cancer | Recruiting | 2026-09-23 |
| NCT07315750 | A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus… | Gastric Carcinoma | Recruiting | 2026-09-22 |
| NCT07416474 | RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy… | Non-Small Cell Lung Cancer | Recruiting | 2026-07-14 |
| NCT07249632 | A Study of Telitacicept in Patients With Ocular Myasthenia Gravis (OMG) | Myasthenia Gravis, Ocular | Recruiting | 2026-04-09 |
| NCT05302284 | A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial… | Urothelial Carcinoma | Recruiting | 2023-12-18 |
| NCT07829549 | Phase III Study of RC148 Plus Chemotherapy Versus Tislelizumab Plus Chemotherapy as… | Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations | Not Yet Recruiting | 2026-09-22 |
| NCT07495033 | Phase III Clinical Trial of Telitacicept Injection in the Treatment of Patients With… | CTD-ILD | Not Yet Recruiting | 2026-04-09 |
| NCT05799287 | A Study of Telitacicept for IgA Nephropathy (TELIGAN) | Primary IgA Nephropathy | Active, Not Recruiting | 2025-12-16 |
| NCT06944496 | A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus… | Gastric Carcinoma | Not Yet Recruiting | 2025-04-25 |
| Phase 2/3 | ||||
| NCT07462143 | A Phase Ⅱ/Ⅲ Clinical Trial of RC148 Plus Chemotherapy as 1L Therapy for Unresectable or… | Colorectal (Colon or Rectal) Cancer | Recruiting | 2026-05-22 |
| NCT06221748 | DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and… | Gastric Cancer | Recruiting | 2024-04-03 |
| NCT05980481 | A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic… | Gastric Cancer | Active, Not Recruiting | 2025-09-29 |
| Phase 2 | ||||
| NCT06178159 | DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With… | Breast Cancer | Recruiting | 2025-10-01 |
| NCT06962865 | A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment… | Non-Small Cell Lung Cancer | Recruiting | 2025-07-16 |
| NCT06642545 | Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ±… | Breast Cancer | Recruiting | 2025-02-17 |
| NCT06389006 | To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab… | Breast Cancer | Recruiting | 2024-05-23 |
| NCT06227117 | Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in… | Breast Cancer | Recruiting | 2024-03-19 |
| NCT06155396 | A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line… | Cervical Cancer | Recruiting | 2024-02-28 |
| NCT06155383 | Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal… | Gastric Cancer | Recruiting | 2023-12-14 |
| NCT05943379 | RC48-ADC in Combination With Gemcitabine in High Risk NMIBC Subjects | NMIBC | Recruiting | 2023-07-13 |
| Phase 1/2 | ||||
| NCT07537881 | A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC288 in the Treatment… | Solid Tumors | Recruiting | 2026-09-23 |
| NCT07105215 | A I/II Phase Clinical Study to Evaluate the Safety and Efficacy of RC278 in the Treatment… | Solid Tumors | Recruiting | 2025-11-26 |
| NCT05205850 | A Study of RC118 in Patients with Locally Advanced Unresectable or Metastatic Malignant… | Advanced Solid Tumor | Recruiting | 2025-01-27 |
| NCT06016062 | A Study of RC148 As a Single Agent and Combination Therapy in Patients with Locally… | Solid Tumor | Recruiting | 2025-01-23 |
| NCT06378242 | To Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of… | High-risk Non-muscle Invasive Bladder Cancer | Recruiting | 2024-07-11 |
Breast Cancer (5) · Gastric Cancer (5) · Non-Small Cell Lung Cancer (NSCLC) (5) · Lung Cancer (4) · Bladder Cancer (3) · Cervical Cancer (1) · Myasthenia Gravis (1)